"Substantial Improvement" Standard, 50% Cap Remain In Inpatient PPS Rule
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers will be allowed to appeal to a CMS advisory panel for reconsideration of whether a new technology qualifies as a "substantial improvement" in the diagnosis and treatment of Medicare beneficiaries, according to the agency's inpatient prospective payment system (PPS) final rule.
You may also be interested in...
Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices
Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion
Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices
Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion
Medtronic InFuse New Technology Add-On Payment Hinges On FDA Approval
Medtronic's InFuse bone graft/LT-Cage lumbar tapered fusion device will be the first product to receive a new technology "add-on" payment under the inpatient prospective payment system (IPPS), provided FDA grants the device PMA approval before publication of the FY 2003 final rule